Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
Results Follow ACTIVATE Study Data In December
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
You may also be interested in...
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.